Growth Hormone–Releasing Peptide

Sermorelin

GHRH(1–29) • GRF(1–29)

Sermorelin is a synthetic 29-amino-acid fragment of growth hormone–releasing hormone that stimulates the pituitary to produce a physiological pulse of growth hormone. It is studied and used for growth-hormone deficiency, sleep, recovery, body composition, and age-related decline in GH signaling.

Sleep Recovery Body Composition Pulsatile GH Release

Protocol Snapshot

Quick reference before the deep dive

Verified Vendors

Sermorelin

Compare Verified Vendors

Current price and availability
Price per mg and vial-size comparison
Testing and fulfillment details

Compare

View Price Index

Daily Dose

200–500mcg

Once daily, typically before bed while fasted.

Cycle Length

3–6 Months

Body-composition effects are usually gradual.

Class

GHRH Analog

Stimulates pituitary GH release through the GHRH receptor.

Length

29 Amino Acids

Contains the biologically active portion of native GHRH.

Peptide Grade

GradeC

Historical approval and a legitimate GHRH mechanism give Sermorelin credibility, but modest, slow results and stronger modern alternatives limit its practical value.

Research Community Safety

Foundation

Research context, mechanisms, and practical use cases

What Is Sermorelin?

Sermorelin is a synthetic version of growth hormone–releasing hormone, commonly abbreviated GHRH. It contains the first 29 amino acids of the full 44-amino-acid hormone produced by the hypothalamus and retains the portion required to activate the pituitary GHRH receptor.

Also known as GHRH(1–29) or GRF(1–29), Sermorelin stimulates the pituitary to release the body’s own growth hormone rather than supplying growth hormone directly. The resulting pulse remains subject to normal somatostatin feedback, helping preserve a more physiological release pattern.

Short Signal, Natural Pulse

Sermorelin has an approximate plasma half-life of only 10–20 minutes because it is rapidly degraded by DPP-4. That short exposure produces a brief pituitary signal followed by a growth hormone pulse that resembles the body’s natural pattern.

Growth hormone released from the pituitary acts on the liver and other tissues to increase IGF-1, which participates in protein synthesis, fat metabolism, tissue repair, collagen production, and other downstream effects.

Sermorelin Benefits

Sermorelin has an established biological mechanism and historical clinical use, but evidence for anti-aging, performance, and body-composition outcomes in healthy adults is more limited than the pediatric growth-deficiency literature.

Physiological GH Release

Sermorelin stimulates pituitary growth hormone secretion while preserving pulsatility and somatostatin feedback.

Sleep Quality

Bedtime use is intended to align with the body’s largest natural nighttime GH pulse. Improved sleep is one of the earliest and most common community reports.

Recovery

Higher GH and IGF-1 signaling may support protein synthesis, collagen production, and recovery between training sessions.

Body Composition

GHRH research in older adults has reported gradual increases in lean mass and reductions in body fat over several months.

Cognitive Support

Some small studies of GHRH in older adults reported improvements in working memory, planning, attention, and processing speed.

Pituitary Stimulation

Unlike injected HGH, Sermorelin stimulates rather than bypasses the pituitary. Claims that this preserves pituitary function remain mechanistically plausible but not definitively proven.

Protocol Planning

Dosing, cycling, and preparation

Sermorelin Dosing Protocol

No modern adult dose-finding study has established an optimal wellness or performance protocol. The ranges below reflect common community and clinic practice rather than the former weight-based pediatric schedule.

Community Protocol

Dose

200–500mcg once daily

Timing

Approximately 30 minutes before bed

Fasting

At least 2 hours after food

Route

Subcutaneous injection

Cycle

3–6 months

Planning Notes

Start

Begin at the lower end to assess response and tolerability

Adjustment

Base changes on IGF-1, glucose, side effects, and the intended outcome—not on reaching the highest dose

Response

Sleep and recovery may be noticed earlier; body-composition changes are typically slower and less predictable

Longer Use

Extended protocols should be reassessed rather than continued automatically when no measurable benefit appears

Fasting Matters

Food—especially carbohydrate-heavy meals—raises insulin and may blunt the growth hormone response. Bedtime dosing is commonly used because it naturally creates a fasting window and aligns with nocturnal GH release.

Sermorelin Reconstitution

5mg Vial + 2mL BAC Water

Strength

2.5mg/mL

Low — 200mcg

8 units on a U-100 syringe

High — 500mcg

20 units on a U-100 syringe

Reconstitution Calculator

Handling Notes

Storage

Refrigerate at 2–8°C after reconstitution

Injection Sites

Abdomen or thigh; rotate sites

Anecdotal Data Points

Community-reported outcomes and recurring patterns

Self-reported anecdotal experiences aggregated from public & private peptide community discussions and anonymous peptideprotocols.app user reports. This information does not carry the same weight as published research.

Positive Reports

Deeper, more restorative sleep is the most consistently reported early effect.
Reduced soreness and faster recovery between training sessions are often reported after several weeks.
Gradual improvements in waist measurement or body composition are reported by some users after several months.
Some users report improved mood, daytime energy, mental clarity, or libido.

Negative Reports

Some users report no meaningful change despite several months of use.
Injection-site irritation, brief facial flushing, headache, and increased hunger are commonly mentioned.
Effects are frequently described as subtler and slower than CJC-1295 or tesamorelin.
Some users report diminishing effects or an IGF-1 plateau after extended use.
Daily injections and months of use can make the cost and inconvenience difficult to justify when results remain subtle.

Stacking & Synergy

Potential Sermorelin pairings and tracking context

Relevant Combinations

Sermorelin + Ipamorelin

The most common pairing. Sermorelin activates the GHRH receptor while Ipamorelin activates the ghrelin receptor, producing a larger GH pulse than either pathway alone.

Sermorelin + BPC-157 / TB-500

These compounds act through different pathways and are sometimes combined for separate recovery goals. Keep Sermorelin on its fasting schedule.

Sermorelin + GLP-1 Agonists

No established direct interaction is known with semaglutide, tirzepatide, or retatrutide, but glucose and nutritional intake should still be monitored.

Sermorelin + Resistance Training

Training and adequate protein provide the practical foundation for evaluating recovery or body-composition changes instead of attributing normal progress to Sermorelin alone.

Free with login

Track in Journal

Track Sermorelin with the markers that matter most for this compound.

Sleep quality and morning recovery.
Training soreness and recovery time.
Weight, waist, appetite, and swelling.

Start Tracking

Common Questions

Practical Sermorelin answers

Is Sermorelin the same as HGH?

No. Sermorelin signals the pituitary through the GHRH receptor; injected HGH supplies growth hormone directly and bypasses that step.

Why is it usually taken before bed?

Bedtime use creates a practical fasting window and is intended to align the signal with the body's largest nocturnal GH pulse.

How quickly are effects noticed?

Sleep or recovery changes may appear first, while measurable body-composition changes—when they occur—usually develop more slowly.

Was Geref discontinued for safety reasons?

FDA determined that the former Geref products were not withdrawn for reasons of safety or effectiveness, but no currently marketed FDA-approved Sermorelin product exists.

Safety Notes

Side effects, contraindications, and precautions

Sermorelin Side Effects

Sermorelin has generally been well tolerated in clinical use, with injection-site reactions and brief flushing among the most frequently reported adverse effects.

Sermorelin raises growth hormone and IGF-1 signaling. Long-term use should include clinical monitoring, especially in people with diabetes risk, active malignancy, thyroid disease, intracranial disease, or unexplained swelling and joint symptoms.

In Published Research

Injection-site pain, redness, or swelling was reported in approximately one in six treated pediatric patients.
Brief facial flushing, headache, dizziness, somnolence, hyperactivity, dysphagia, and urticaria have been reported less often.
Small acute changes in cortisol, prolactin, FSH, or LH have been reported inconsistently across studies.

What Users Report

Common: injection-site irritation, flushing, headache, or increased hunger.
Less common: water retention, tingling, joint discomfort, fatigue, or sleep disruption.
Changes in fasting glucose or insulin sensitivity are possible as IGF-1 rises.

Sermorelin Contraindications and Precautions

Do Not Use If You Have

Active cancer or an unevaluated tumor.
Known hypersensitivity to Sermorelin or formulation ingredients.
An untreated intracranial lesion or pituitary mass that has not been evaluated.
Pregnancy or breastfeeding.

Use Caution With

A prior history of malignancy because increasing GH and IGF-1 signaling may be inappropriate in some cancer contexts.
Untreated hypothyroidism, which can substantially reduce response.
Diabetes, insulin resistance, or significant hyperglycemia.
Epilepsy or another seizure disorder.
Untreated sleep apnea, edema, carpal-tunnel symptoms, or significant joint pain.

Drug Interactions

Glucocorticoids may reduce Sermorelin effectiveness. Thyroid hormone status strongly affects the GH axis, and untreated hypothyroidism should be addressed first. Avoid combining Sermorelin with direct growth hormone injections unless specifically managed by a qualified clinician.

Monitoring

Monitor IGF-1, fasting glucose or HbA1c when appropriate, thyroid function, blood pressure, body weight, waist measurement, edema, joint symptoms, and sleep quality. Persistent headaches, visual changes, or neurological symptoms require medical evaluation.

Regulatory Status

Sermorelin was previously FDA approved as Geref for pediatric growth hormone deficiency, but the commercial product was discontinued. Current compounded Sermorelin use in the United States is off-label and is not equivalent to an actively marketed FDA-approved product.

FINAL VERDICT

Peptide Protocol's Opinionated Opinion

This is not medical advice. This editorial is our own opinion piece based off the experience of our own lab rats.

Sermorelin carries old-school credibility as a formerly FDA-approved GH secretagogue, but its practical results are modest and slow. Newer options such as CJC-1295 + Ipamorelin tend to deliver stronger, more reliable GH pulses and better recomp and recovery for most community users, often with comparable or cleaner profiles. Tesamorelin offers another more compelling option when visceral-fat reduction is the priority.

Sermorelin is not terrible—it is simply yesterday's compound. For most stacks, we would skip it in favor of better tools.